These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 32685588)

  • 1. Clinical and Economic Outcomes in Low-risk Pulmonary Embolism Patients Treated with Rivaroxaban versus Standard of Care.
    Peacock WF; Coleman CI; Wells P; Fermann GJ; Wang L; Baser O; Schein J; Crivera C
    J Health Econ Outcomes Res; 2019; 6(3):160-173. PubMed ID: 32685588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overall Effectiveness of Rivaroxaban in Patients with Pulmonary Embolism.
    Wang L; Baser O; Wells P; Peacock WF; Coleman CI; Fermann GJ; Schein J; Crivera C
    Clin Ther; 2017 Jul; 39(7):1426-1436.e2. PubMed ID: 28652016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefit of early discharge among patients with low-risk pulmonary embolism.
    Wang L; Baser O; Wells P; Peacock WF; Coleman CI; Fermann GJ; Schein J; Crivera C
    PLoS One; 2017; 12(10):e0185022. PubMed ID: 29016692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of sPESI for risk stratification in patients with pulmonary embolism.
    Wells P; Peacock WF; Fermann GJ; Coleman CI; Wang L; Baser O; Schein J; Crivera C
    J Thromb Thrombolysis; 2019 Jul; 48(1):149-157. PubMed ID: 30729377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rivaroxaban versus Heparin Bridging to Warfarin Therapy: Impact on Hospital Length of Stay and Treatment Costs for Low-Risk Patients with Pulmonary Embolism.
    Weeda ER; Kohn CG; Peacock WF; Fermann GJ; Crivera C; Schein JR; Coleman CI
    Pharmacotherapy; 2016 Oct; 36(10):1109-1115. PubMed ID: 27548074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hospitalizations and Other Health Care Resource Utilization Among Patients with Deep Vein Thrombosis Treated with Rivaroxaban Versus Low-molecular-weight Heparin and Warfarin in the Outpatient Setting.
    Deitelzweig S; Laliberté F; Crivera C; Germain G; Bookhart BK; Olson WH; Schein J; Lefebvre P
    Clin Ther; 2016 Aug; 38(8):1803-1816.e3. PubMed ID: 27491278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Shortened hospital length of stay and lower costs associated with rivaroxaban in patients with pulmonary embolism managed as observation status.
    Weeda ER; Peacock WF; Fermann GJ; Baugh CW; Wells PS; Ashton V; Crivera C; Wildgoose P; Schein JR; Coleman CI
    Int J Clin Pract; 2017 Jan; 71(1):. PubMed ID: 28097761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Healthcare costs associated with rivaroxaban or warfarin use for the treatment of venous thromboembolism.
    Coleman CI; Baugh C; Crivera C; Milentijevic D; Wang SW; Lu L; Nelson WW
    J Med Econ; 2017 Feb; 20(2):200-203. PubMed ID: 27780397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effectiveness, safety, and costs of rivaroxaban and warfarin among morbidly obese patients with atrial fibrillation.
    Peterson ED; Ashton V; Chen YW; Wu B; Spyropoulos AC
    Am Heart J; 2019 Jun; 212():113-119. PubMed ID: 30981035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is Rivaroxaban Associated With Shorter Hospital Stays and Reduced Costs Versus Parenteral Bridging to Warfarin Among Patients With Pulmonary Embolism?
    Coleman CI; Fermann GJ; Weeda ER; Wells PS; Ashton V; Crivera C; Bunz TJ; Wildgoose P; Schein JR; Peacock WF
    Clin Appl Thromb Hemost; 2017 Oct; 23(7):830-837. PubMed ID: 27481875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hospital length-of-stay and costs among pulmonary embolism patients treated with rivaroxaban versus parenteral bridging to warfarin.
    Weeda ER; Wells PS; Peacock WF; Fermann GJ; Baugh CW; Ashton V; Crivera C; Wildgoose P; Schein JR; Coleman CI
    Intern Emerg Med; 2017 Apr; 12(3):311-318. PubMed ID: 27757790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter Trial of Rivaroxaban for Early Discharge of Pulmonary Embolism From the Emergency Department (MERCURY PE): Rationale and Design.
    Singer AJ; Xiang J; Kabrhel C; Merli GJ; Pollack C; Tapson VF; Wildgoose P; Peacock WF
    Acad Emerg Med; 2016 Nov; 23(11):1280-1286. PubMed ID: 27537530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulmonary Embolism Inpatients Treated With Rivaroxaban Had Shorter Hospital Stays and Lower Costs Compared With Warfarin.
    Margolis JM; Deitelzweig S; Kline J; Tran O; Smith DM; Crivera C; Bookhart B; Schein J
    Clin Ther; 2016 Nov; 38(11):2496-2503. PubMed ID: 27751675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emergency Department Discharge of Pulmonary Embolus Patients.
    Frank Peacock W; Coleman CI; Diercks DB; Francis S; Kabrhel C; Keay C; Kline JA; Manteuffel J; Wildgoose P; Xiang J; Singer AJ
    Acad Emerg Med; 2018 Sep; 25(9):995-1003. PubMed ID: 29757489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study.
    Ageno W; Mantovani LG; Haas S; Kreutz R; Monje D; Schneider J; van Eickels M; Gebel M; Zell E; Turpie AG
    Lancet Haematol; 2016 Jan; 3(1):e12-21. PubMed ID: 26765643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Healthcare Resource Utilization and Costs of Rivaroxaban Versus Warfarin Among Nonvalvular Atrial Fibrillation Patients with Obesity and Diabetes.
    Weir MR; Chen YW; He J; Bookhart B; Campbell A; Ashton V
    Diabetes Ther; 2021 Dec; 12(12):3167-3186. PubMed ID: 34699020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Healthcare resource utilization and costs associated with venous thromboembolism in cancer patients treated with anticoagulants.
    Streiff M; Milentijevic D; McCrae KR; Laliberté F; Lejeune D; Lefebvre P; Schein J; Khorana AA
    J Med Econ; 2019 Nov; 22(11):1134-1140. PubMed ID: 31106638
    [No Abstract]   [Full Text] [Related]  

  • 18. Shorter Hospital Stays and Lower Costs for Rivaroxaban Compared With Warfarin for Venous Thrombosis Admissions.
    Margolis JM; Deitelzweig S; Kline J; Tran O; Smith DM; Bookhart B; Crivera C; Schein J
    J Am Heart Assoc; 2016 Oct; 5(10):. PubMed ID: 27792638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shortened length of hospital stay with rivaroxaban in patients with symptomatic venous thromboembolism in Japan: the J-EINSTEIN pulmonary embolism and deep vein thrombosis program.
    Matsuo H; Prins M; Lensing AW; Fujinuma EW; Miyamoto Y; Kajikawa M
    Curr Med Res Opin; 2015 Jun; 31(6):1057-61. PubMed ID: 25851062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between rivaroxaban use and length of hospital stay, treatment costs and early outcomes in patients with pulmonary embolism: a systematic review of real-world studies.
    Kohn CG; Fermann GJ; Peacock WF; Wells PS; Baugh CW; Ashton V; Crivera C; Schein JR; Wildgoose P; Coleman CI
    Curr Med Res Opin; 2017 Sep; 33(9):1697-1703. PubMed ID: 28665208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.